CNOT3
CNOT3 (CCR4-NOT transcription complex subunit 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Leukaemia, Non-Hodgkin lymphoma and 4 more.
Overview
Component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation. Additional complex functions may be a consequence of its influence on mRNA expression. May be involved in metabolic regulation; may be involved in recruitment of the CCR4-NOT complex to deadenylation target mRNAs involved in energy metabolism.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes affected pathway 0.33, literature 0.72, genetic association 0.00, somatic mutation 0.84, animal model 0.25). IntOGen calls it a driver in 3 cohorts (3 activating, 0 loss-of-function), covering Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Prostate Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CNOT3 (CCR4-NOT transcription complex subunit 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Leukaemia, Non-Hodgkin lymphoma and 4 more.
- 1 · What it is
CNOT3 (CCR4-NOT transcription complex subunit 3) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Leukaemia, Non-Hodgkin lymphoma and 4 more.
- 2 · What goes wrong in cancer
Component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation.
- 3 · How drugs use it
No product in this corpus aims at CNOT3 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:7879 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75175 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000088038 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: melanoma 0.55, acute lymphoblastic leukaemia 0.54, non-Hodgkin lymphoma 0.55, skin cancer 0.54, leukaemia 0.56 (GraphQL API, CC0)); IntOGen CNOT3 (driver in 3 cohorts (Act 3, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of the CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation. Additional complex functions may be a consequence of its influence on mRNA expression. May be involved in metabolic regulation; may be involved in recruitment of the CCR4-NOT complex to deadenylation target mRNAs involved in energy metabolism. Involved in mitotic progression and regulation of the spindle assembly checkpoint by regulating the stability of MAD1L1 mRNA. Can repress transcription and may link the CCR4-NOT complex to transcriptional regulation; the repressive function may involve histone deacetylases. Involved in the maintenance of embryonic stem (ES) cell identity. Location: Cytoplasm; Nucleus; Cytoplasm, P-body (UniProt). Locus 19q13.42 (HGNC).
- Prostate cancer: IntOGen driver in 2 cohorts (PRAD)
- Leukaemia: Open Targets association 0.56 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.55 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
- Chronic lymphocytic leukaemia: IntOGen driver in 1 cohort (CLLSLL)
- Melanoma: Open Targets association 0.55 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CNOT3" OR ABSTRACT:"CNOT3" OR TITLE:"CCR4-NOT transcription complex subunit 3" OR ABSTRACT:"CCR4-NOT transcription complex subunit 3" OR TITLE:"NOT3H" OR ABSTRACT:"NOT3H" OR TITLE:"KIAA0691" OR ABSTRACT:"KIAA0691" OR TITLE:"LENG2" OR ABSTRACT:"LENG2" OR TITLE:"NOT3" OR ABSTRACT:"NOT3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CNOT3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetAFF1
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetZMYM2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, IntOGen.
- TargetTAL1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetBIRC3
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), IntOGen.
- TargetMED12
Shares Leukaemia (all types), Chronic lymphocytic leukaemia, Skin cancer (all types), Acute lymphoblastic leukaemia.
- TargetLEF1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia.
- TargetMLLT3
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), IntOGen, Melanoma.